We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Fc Effector Bioassays for Rapid Quantitative Measurement of ADCC and ADCP Mechanisms of Action Poster

SEARCH POSTERS

Abstract

Zhi-jie Jey Cheng, Rich Moravec, Aileen Paguio, Denise Garvin, Frank Fan and Mei Cong
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711, USA

Drug developers and regulatory authorities recognize antibody dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP) as important mechanisms of action (MOA) of therapeutic antibodies. Traditional ADCC and ADCP bioassays use primary cells, which are labor intensive and highly variable. Less variable, easy-to-use and consistent analysis of these important MOA is needed in drug development programs. To meet this need, we have developed a suite of functional cell-based Fc Effector reporter bioassays for the following receptors: Human FcγRIIIa (V158 and F158 variants); Human FcγRIIa (H131 and R131 variants); Human FcγRI;  Mouse FcγRIV & FcγRIII.

Each bioassay is provided in “thaw-and-use” format for a rapid and convenient workflow and further reduction in assay variability. In qualification studies according to ICH guidelines, the bioassays show specificity, accuracy, precision, and linearity enabling their use in antibody screening, characterization, stability and potency studies.

Document Icon Download the poster PDF (579kb)

  • Part# PS288
  • Printed in USA.